Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04978571

Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)

The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms.

An additional purpose of this study is to demonstrate that PENFS improves functioning in children with post Covid-19 symptoms.

Recruiting

Interested in participating?

Request Info

Key information

About this study

The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms. Patient will be offered a Neurostim device. This device is placed on the outer ear through tiny needles. Since this is a randomized trial, patients may receive an active (experiment) or nonactive (control) Neurostim device. However, the nonactive control Neurostim device group will be given the option to receive an active device after the initial study procedures. The experiment group may be in this study up to 8 weeks and the control group may be in this study up to 12 weeks. The control group will have 4 additional weeks due to the transition to an active device following the first 8 weeks. The device is worn weekly for 4 weeks. Each device is worn for 5 consecutive days for the full 24 hours. The participant will be able to easily take the device off on the 6th day. Study procedures include: Neurological testing- a balance test and computerized neurological standard testing, Cardiology testing- electrocardiogram for heart rate variability (heart electrical pulse test), a pupilometer (eye) test, and parent/child questionnaires. You may benefit from this research, but there is no guarantee that being in this study will help you.

Patients in the COVID arm will be offered 6 placements of Neurostim devices. This device is placed on the outer ear through tiny needles. Patients in this arm will not be randomized, all patients will receive active devices. This group will be in the study for up to 10 weeks. The device is worn weekly for 6 weeks. Each device is worn for 5 consecutive days for the full 24 hours. The patient will be able to remove the device on the 6th day. Study procedures include: Neurological testing called Cognigram to measure cognitive functioning and parent/child questionnaires. After 6 weeks of device placements, parent and child will complete a 1-week and 1-questionnaires. You may benefit from this research, but there is no guarantee that being in this study will help you.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Concussion:

Inclusion criteria

  • Clinical diagnosis of Post-Concussion Syndrome
  • Post-Concussion Symptoms for at least 3 months along with lack of other explanation for their symptoms
  • English and Spanish-speaking families

Exclusion criteria

  • Seizure disorders
  • Significant developmental delay
  • Infection or severe dermatological condition of ear
  • Bleeding disorders
  • Implanted electrical device

COVID:

Inclusion criteria

  • Child is in between the ages 11-18
  • Child is present at CHOC Neurology clinic post covid-19 symptoms of more than 3 months duration along with lack of other explanation for their symptoms
  • English-speaking and Spanish-speaking families

You cannot participate in this study if you meet the following exclusion criteria:

  • Children with significant developmental delay, infection or severe dermatological condition of ear, bleeding disorders, or having any implanted electrical device will be excluded.
  • Are not able to attend Friday appointments for the Neurostim placements.

Treatment and study plan

percutaneous electrical nerve-field stimulation, PENFS

Device

A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear

percutaneous electrical nerve-field stimulation, PENFS (sham device)

Device

A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear. The sham device will not deliver field stimulation to the ear.

percutaneous electrical nerve-field stimulation, PENFS (COVID active device)

Device

A novel, FDA approved for commercial use, cleared device that delivers field stimulation with alternating frequencies to the external ear

Primary outcomes

  1. Immediate Post-Concussion Assessment

    Time frame: 8 weeks

    With the Immediate Post-Concussion Assessment, percentiles indicate functioning assessment after a concussion. Having a higher score on this assessment implies having a worse outcome assessment.

  2. Post-Concussion Symptom Scale

    Time frame: 8 weeks

    Post Concussion Symptom Scale- a 22 item questionnaire, rated on a 0-6 scale. Having a higher score indicates having worse symptom assessment.

  3. Balance Error Scoring Symptom

    Time frame: 8 weeks

    Balance Error Scoring Symptom- a balance test conducted in person. Patient is asked to do a 3 poses on the floor and 3 poses standing on a foam and asked to stand still. The amount of errors will be counted for the times the patient moves. The higher the errors, means patient does not have a well-balance.

  4. COGNIGRAM

    Time frame: 10 weeks

    COGNIGRAM is a test prescribed by clinicians to measure cognitive function.

Secondary outcomes

  1. Abdominal Pain Index

    Time frame: 8 weeks

    4 item to rate abdominal pain. Higher score indicates having worse outcome.

  2. Baxter Animated Retching Faces Nausea Scale

    Time frame: 8 weeks

    rate on a 1-10 scale level of nausea. Higher score indicated feeling worse.

  3. Children's Somatization inventory

    Time frame: 8 weeks

    23 item to rate symptoms, higher score indicates worse symptoms

  4. Functioning disability inventory

    Time frame: 8 weeks

    15 item, asking on functioning, higher score indicated worse outcome.

  5. Patient-Reported Outcomes Measurement Information System- Anxiety

    Time frame: 8 weeks

    8 item questionnaire asking on anxiety level. Higher score indicates worse outcome.

  6. Patient-Reported Outcomes Measurement Information System- Depression

    Time frame: 8 weeks

    8 item asking on depression, higher score indicated worse outcome

  7. Patient-Reported Outcomes Measurement Information System-Global health scales

    Time frame: 8 weeks

    7-item asking on general health, lower score indicates worse outcome

  8. Covid-19 questionnaire

    Time frame: 10 weeks

    40-item asking Covid related symptoms and history.

Other outcomes

  1. Orthostatic Vitals

    Time frame: 8 weeks

    numerical number that determines blood pressure. Having a high blood pressure indicates worse outcome. Reading will be done by a provider.

  2. Electrocardiography

    Time frame: 8 weeks

    Heart rate measurement- a recording of electrical signal from the heart to check for heart conditions. Reading will be done by a provider.

  3. Pupillometry

    Time frame: 8 weeks

    Pupillometry: An eye assessment to measure pupil size and reactivity, reading will be done by a provider

Study contacts

Contact information is provided by the study sponsor or research team.

Jamie Janchoi

CONTACT

[email protected]

714-509-8765

Pari Mokhtari

CONTACT

[email protected]

714-509-8765

Sponsors and collaborators

Lead sponsor

Children's Hospital of Orange County

Other

Collaborators

  • Innovative Health Solutions

Registry information

Official study title

A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)

Important dates

Study start
2021
Primary completion
2026
Study completion
2027
First posted
Jul 27, 2021
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.